Citations

Clear

6729 citation(s) found for "Li, Mark".

Circulating levels of insulin‐like growth factor I ( IGF ‐I) and risk of multiple myeloma: An observational and Mendelian randomisation study
Benavente, Yolanda, Hermosa, Sara, Clay‐Gilmour, Alyssa, Brown, Elizabeth , Hofmann, Jonathan N., Rothman, Nathaniel, Lan, Qing, Berndt, Sonja I., Albanes, Demetrius, Purdue, Mark, Chanock, Stephen J., Norman, Aaron, Kumar, Shaji K., Vachon, C M, Novak, Anne J. , Ghesquieres, Herve, Bracci, Paige M., Holly, Elizabeth, Griffin, Rosalie G., Vermeulen, Roel , Hjalgrim, Henrik, Smedby, Karin Ekström, Cheah, Simon , Monnereau, Alain, Arslan, Alan, Zhang, Yawei, Camp, Nicola J., Sborov, Douglas W., Ziv, Elad , Joseph, Vijai, Teras, Lauren R., Patel, Alpa V. , Vajdic, Claire M., Cocco, Pierluigi, Alemany, Laia, McKay, James, Casabonne, Delphine , Monnereau, Alain , Brown, Elizabeth E , Machiela, Mitchell J , Slager, Susan L , Cerhan, James R , Rajkumar, S Vincent , Novak, Anne J , Habermann, Thomas , Salles, Gilles A , Hildebrandt, Michelle A T , Jayasekara, Harindra , Cheah, Simon , Kane, Eleanor , Guilloteau, Adrien , Casabonne, Delphine , Ziv, Elad , Benavente, Yolanda , Papadimitriou, Nikos , Clay‐Gilmour, Alyssa , Hofmann, Jonathan N. , Rothman, Nathaniel , Lan, Qing , Berndt, Sonja I. , Albanes, Demetrius , Machiela, Mitchell J. , Chanock, Stephen Jacob , Bhatti, Parveen , Cozen, Wendy , Slager, Susan L. , Cerhan, James R. , Rajkumar, S. Vincent , Habermann, Thomas M. , Link, Brian K. , Salles, Gilles , Ghesquières, Hervé , Bracci, Paige M. , Waller, Rosalie G. , Hildebrandt, Michelle A.T. , Kolijn, Pieter Martijn , Hjalgrim, Henrik , Jayasekara, Harindra , Chen, Yu , Camp, Nicola J. , Sborov, Douglas W. , Osman, Afaf E.G. , Vivo, Immaculata De , Teras, Lauren R. , Kane, Eleanor , Vajdic, Claire M. , Alemany, Laia, Sáinz, Juan , McKay, James, Birmann, Brenda M.

Mayo Clinic

British Journal of Haematology | March 24, 2026 | Volume: 208 | Issue: 6 | Pages: 1942-1953

10.1111/bjh.70444 | PMID 41873017 Get It

Summary Evidence for an association between insulin‐like growth factors (IGF) and multiple myeloma (MM) is inconsistent. We examined total IGF‐I concentrations and risk of MM by combining baseline serological data among UK Biobank participants ( n = 444 187; 732 incident MM) with a two‐sample Mendelian randomisation (MR) analysis using identified genetic variants associated with circulating total IGF‐I and IGF‐binding protein 3 (IGFBP‐3) in the InterLymph consortium (2434 MM and their 2567 controls). Finally, additional lymphoid neoplasm (LN) subtypes were included for comparison with the main hypothesis. Circulating IGF‐I level was positively associated with MM risk Hazard ratio‐HR‐per one standard deviation‐SD‐increase (HR 1‐SD = 1.11, 95% confidence interval [CI]: 1.01–1.22; p ‐value = 0.03), especially closer to diagnosis. Genetically inferred IGF‐I levels were associated with increased MM risk (odds ratio [OR] = 1.27, 95% CI: 1.05–1.54) but not with any other LNs. Genetically inferred IGFBP‐3 levels showed no associations with any LN evaluated. Corroborating previous findings, in a secondary analysis, IGF‐I levels were associated with the risk of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) in males with higher body mass index (HR 1‐SD in obese male = 1.36, 95% CI: 1.14–1.61). Our serological and MR analyses suggest a contributing role of IGF‐I in the susceptibility of MM; the CLL/SLL findings warrant further investigation considering sex‐specific adiposity.
Abstract B032: Drug and single-cell gene expression integration identifies heterogeneity-aware synergistic combinations for glioblastoma
Suter, Robert K. , Jermakowicz, Anna, Veeramachaneni, Rithvik, D'Antuono, Matthew, Zhang, L.G., Chowdary, Rishika , Kaeppeli, Simon , Sharp, Madison, Palwai, Pravallika, Stathias, Vasileios , Baker, Grace, Ruiz, Luz , Walters, Winston, Cepero, Maria, Reilly, Edward B. , Oleksijew, Anatol, Anderson, Mark G. , Williams, Sion Ll., Komotar, Ricardo J., Fuente, Macarena I. de la , Stein, Gregory , Wojcinski, Alexandre , Schürer, Stephan C. , Ayad, Nagi , Jermakowicz, Anna M. , D’Antuono, Matthew , Palwai, Pravallika, Cepero, Maria L., Burgenske, Danielle M. , Ivan, Michael E , Stein, Gregory, Kesari, Santosh , Sarkaria, Jann N. , Ayad, Nagi G.

Mayo Clinic

Cancer Research | March 23, 2026 | Volume: 86 | Issue: 6_Supplement | Pages: B032-B032

10.1158/1538-7445.brain26-b032 Get It

Abstract Glioblastoma (GBM) remains the most common and lethal adult malignant primary brain cancer with few treatment options. A significant issue hindering GBM therapeutic development is intratumor heterogeneity and plasticity. GBM tumors contain neoplastic cells within a fluid spectrum of diverse transcriptional states. Identifying effective therapeutics requires a platform that predicts the differential sensitivity and resistance of these states to various treatments. Here, we develop scFOCAL (Single-Cell Framework for -Omics Connectivity and Analysis via L1000), to quantify the cellular drug sensitivity and resistance landscape. Using single-cell RNA sequencing of newly diagnosed and recurrent GBM tumors, we identify compounds from the LINCS L1000 database with transcriptional response signatures selectively discordant with distinct GBM cell states, and leverage this capability to predict combination synergy. We validate the significance of these findings in vitro, ex vivo, and in vivo, and use the Olig2 inhibitor CT-179 as a reference drug to identify additional small molecules that would maximize the cell-drug discordance across the GBM transcriptional landscape. Our analysis leads to the combination of Olig2 inhibition with treatment with Depatux-M, of with which we demonstrate synergy in vivo. Our studies suggest that scFOCAL identifies cell states that are sensitive and resistant to targeted therapies in GBM using a measure of cell and drug connectivity, which can be applied to identify new synergistic combinations. Citation Format: Robert K. Suter, Anna M. Jermakowicz, Rithvik Veeramachaneni, Matthew D'Antuono, Longwei Zhang, Rishika Chowdary, Simon Kaeppeli, Madison Sharp, Pravallika Palwai, Vasileios Stathias, Grace Baker, Luz Ruiz, Winston Walters, Maria Cepero, Danielle Burgenske, Edward B. Reilly, Anatol Oleksijew, Mark G. Anderson, Sion Ll. Williams, Michael E. Ivan, Ricardo J. Komotar, Macarena I. De La Fuente, Gregory Stein, Alexandre Wojcinski, Santosh Kesari, Jann N. Sarkaria, Stephan C. Schürer, Nagi G. Ayad. Drug and single-cell gene expression integration identifies heterogeneity-aware synergistic combinations for glioblastoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Brain Cancer; 2026 Mar 23-25; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(6_Suppl):Abstract nr B032.
Leveraging Machine Learning to Predict Delayed Graft Function Occurrence and Length in Kidney Transplant Recipients
Nica, Alexandru , Mejia, Mateo Velasquez , Abdelrheem, Ahmed, Smith, Byron, Park, Walter D. , Stegall, Mark D. , Heilman, Raymond L. , Smith, Byron H. , Smith, Byron , Park, Walter , Stegall, Mark D , Heilman, Raymond , Jadlowiec, Caroline , Jadlowiec, Caroline C.

Mayo Clinic

Clinical Transplantation | March 23, 2026 | Volume: 40 | Issue: 3 | Pages: No page available

10.1111/ctr.70514 | PMID 41869992 Get It

ABSTRACT Predicting delayed graft function (DGF) relies on donor, recipient, and perioperative factors. Despite the growing recognition that DGF duration strongly influences patient outcomes, no models currently address or predict its impact—highlighting an important gap in current research and clinical practice. This study aimed to develop an ensemble‐based machine learning model using perioperative data to predict DGF occurrence and duration. The gradient‐boosted decision trees model was trained and validated on 2725 patients, with k‐fold cross‐validation in an external cohort of 284 patients. Model performance was evaluated based on accuracy, ROC‐AUC, and other metrics using R and Python libraries. The binary DGF prediction model achieved a ROC‐AUC of 0.77, while the DGF duration classification model had an accuracy of 79.2%. DGF duration AUC values by time interval were 0.76 for 0–1 weeks, 0.81 for >1–2 weeks, 0.80 for >2–3 weeks, and 0.87 for >3 weeks; the overall macro‐averaged AUC was 0.81. The mean Brier score for multi‐class predictions was 0.14. External validation showed a 78% accuracy for DGF duration prediction. Acute kidney injury (AKI) and donor donation after circulatory death (DCD) status were key DGF predictors. The use of gradient‐boosted decision trees (GBDT) improves the prediction of both the likelihood and duration of DGF, addressing a current gap in kidney transplant patient care. By facilitating personalized transplant care, this model supports more effective perioperative planning and timely interventions, which may contribute to better patient outcomes.
Ustekinumab for ileal stricturing Crohn’s disease—an international multicenter retrospective cohort study
Ouali, Sara El , Baker, Mark E, Lu, Cathy , Medellin, A, Bruining, David H, Fletcher, Joel G. , Inoue, Aki, Regueiro, Miguel, Ottichilo, Ronald K. , Schoenoff, Shayla, Rosentreter, Ryan E., Qazi, Taha , Holubar, S. D., Gauriloff, Samantha, Gandhi, Namita , Cohen, Benjamin L, Balci, Numan, Rieder, Florian, Regueiro, Miguel , Lu, Cathy , El Ouali, Sara , Regueiro, Miguel , Qazi, Taha , Sleiman, Joseph , Holubar, Stefan D , Rieder, Florian , Fletcher, Joel G , Baker, Mark E. , Medellin, Alexandra , Bruining, David H. , Inoue, Aki, Bena, Jim , Sleiman, Joseph , Holubar, Stefan D. , Cohen, Benjamin L, Goren, Idan , Rieder, Florian

Mayo Clinic

Journal of Crohn's and Colitis | March 23, 2026 | Volume: 20 | Issue: 3 | Pages: No page available

10.1093/ecco-jcc/jjag038 | PMID 41934342 Get It

Abstract Background & Aims Stricturing Crohn’s disease (CD) is a significant problem, and no selective anti-fibrotic therapies are available. Anti-inflammatory approaches are the mainstay of medical treatment. However, data on the efficacy of ustekinumab (USTE) in ileal stricturing CD are lacking. Our aim was to assess its efficacy in this setting. Methods We performed an international multicenter observational cohort study evaluating adult CD patients who received USTE within 6 months of imaging-confirmed symptomatic stricturing small bowel disease. Outcomes were rates of endoscopic balloon dilation (EBD), surgery, intervention (defined as the composite need for EBD or surgery), recurrent obstructive symptoms, and USTE persistence. Results Fifty-seven patients were included (51% female, median age 43 years). Median follow-up was 17 months. Intervention rates were 35%, 45%, and 69% of patients, at 12, 24, and 48 months, respectively. USTE persistence was 78%, 76%, and 52% at 12, 24, and 48 months. Estimated obstructive symptoms rates were 31% and 49% at 12 and 24 months, respectively. EBD within 6 months prior to starting USTE was associated with an increased risk of intervention. Increased bowel wall thickness on imaging, prior biologic use, and obstructive symptom duration were associated with USTE discontinuation. Occurrence of obstructive symptoms during treatment was associated with prior biologic use, EBD within 6 months of starting USTE, and a lower BMI. Conclusions USTE appears to be an appropriate medical option in biologic-experienced CD patients with ileal strictures. Further prospective data are needed to better define outcomes and predictors of response in this setting.
TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
Stockard, Alyssa , Leibovit-Reiben, Zachary , Hu, Bowen , Jiang, Rundong , Roberts, Bryce T. , Penner, Scott , Li, Xing , Ramirez, Zeni , Stewart, Keegan , Fox, Jennifer , Bogle, Rachael , Zhang, Nan, Shao, Samantha C. , DiCaudo, David J. , Zunich, Samantha , Tsoi, L., Pittelkow, Mark R., Sluzevich, Jason C. , Gudjonsson, Johann E., Leibovit‐Reiben, Zachary , Zhang, Nan , Borges da Silva, Henrique , DiCaudo, David J , Zunich, Samantha , Pincelli, T , Tsoi, Lam C , Pittelkow, Mark R , Sluzevich, Jason C , Gudjonsson, Johann E , Mangold, A R , Penner, S.E., Ramirez, Z., Wasikowski, Rachael, Silva, Henrique Borges da , Pincelli, Thaís , Tsoi, Lam C. , Pittelkow, Mark R. , Mangold, Aaron R.

Mayo Clinic

No container title available | March 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.13.26348272 | PMID 41891048 Get It

Abstract Lichen Planopilaris (LPP) is a lymphocyte-mediated scarring alopecia characterized by progressive follicular destruction and fibrosis. In this clinical trial, patients with biopsy proven LPP were treated with deucravacitinib (an oral inhibitor of tyrosine kinase 2 (TYK2)) 6 mg BID for 24 weeks (NCT-06091956). Bulk and single-cell RNA sequencing was performed on paired pre- and post-treatment scalp biopsies from baseline and week 4. Patients (N=10) demonstrated improvements in PGA (88.9%, p=0.008), LPPAI (−2.3 points, SD 1.1, p=0.002) and Skindex-16 (−21.0 points, SD 22.1, p=0.014) scores at week 24. Bulk transcriptomic analysis of untreated LPP revealed upregulation of type I Interferon (IFN)-stimulated genes and pathways related to inflammation, immune activation, keratinization, and extracellular matrix remodelling, with downregulation of immune and inflammatory pathways following treatment. Single-cell RNA-seq of LPP was characterized by enrichment of CD8+GZMK+ T cells which showed downregulation of T-cell receptor signaling as well as antiviral pathways with treatment. Basal keratinocytes exhibited reduced cytokine and interferon signaling and decreased communication with NK cells following treatment. CCL19+ fibroblasts were prominent in untreated disease was attenuated after treatment, with downregulation of type I IFN signaling. Selective TYK2 inhibition with deucravacitinib effectively suppresses these inflammatory circuits in LPP and represents a promising therapeutic strategy.
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis
Vitis, Luigi Antonio De , Larson, Melissa C., Atkinson, Hunter J., Block, Matthew S. , CLIBY, W, Couch, Fergus J., Dowdy, Sean C., Glaser, Gretchen E., Goergen, Krista M., Goode, E., Gostout, Bobbie S., Hartmann, Lynn C., Heinzen, Ethan P. , Huang, Yajue, Jatoi, Aminah , Jones, Monica B., Karow, Katie J., Keeney, Gary L., Kumar, Amanika, Langstraat, Carrie L., Lee, Sun-Hee , Mariani, A., Ostby, Stuart A. , Peethambaram, Prema P. , Podratz, Karl C. , Shahi, Maryam , Sherman, M., Sommerfield, Marla Kay, Wall, Vonda M., Weroha, S. John, Hendrickson, Andrea E. Wahner , Maurer, Matthew J., Bakkum-Gamez, Jamie, Oberg, Ann L. , Cliby, William A. , Couch, Fergus J. , Larson, Melissa C. , Glaser, Gretchen , Couch, Fergus J. , De Vitis, Luigi A, Jones, Monica, Glaser, Gretchen , Larson, Melissa C , Cliby, William A , Atkinson, Hunter J., Dowdy, Sean C. , Hartmann, Lynn C. , Kumar, Amanika , Langstraat, Carrie , Sherman, Mark E. , Sommerfield, Marla-Kay, Swisher, Elizabeth M. , Wall, Vonda M., Maurer, Matthew J. , Kaufmann, Scott H. , Bakkum‐Gamez, Jamie N.

Mayo Clinic

JCO Oncology Advances | March 20, 2026 | Volume: 3 | Issue: 1 | Pages: No page available

10.1200/oa-25-00142 | PMID 41918500 Get It

PURPOSE To compare mortality risk among long-term survivors of high-grade serous ovarian cancer (HGSOC) with that of the general US population and to examine how mortality and recurrence trends have evolved under changing treatment approaches. MATERIALS AND METHODS This is a retrospective cohort study including patients with histologically confirmed HGSOC treated at a single referral cancer center from 1991 to 2022. Mortality risk, expressed as standardized mortality ratios (SMRs, ratio of observed deaths in the study population to expected deaths in an age-matched US population), was assessed at diagnosis and yearly on patients without events (disease persistence, recurrence, or death from any cause). RESULTS A total of 2,074 consecutive patients were included. The median follow-up was 12.5 years (IQR, 11.7-13.8). Most patients were stage III (1,396, 69.2%), 1,299 (62.8%) underwent primary cytoreductive surgery, and 1,688 (87.4%) received platinum-taxane as first-line therapy. At diagnosis, the mortality rate was 7.40 times higher than that in the general population (95% CI, 7.04 to 7.77). By 7 event-free years, the 95% CI for the SMR included 1 for the first time, and at 10 years, the SMR was 1.05 (95% CI, 0.72 to 1.49), indicating no statistically significant excess mortality compared with the general population. In those event-free at 10 years, the 5-year cumulative incidence of ovarian cancer–related deaths (8.2% [95% CI, 4.2 to 16.0]) was comparable with that of non–ovarian cancer–related deaths (6.3% [95% CI, 2.9 to 13.8]). CONCLUSION In this cohort, mortality risk steadily declined for patients who remained event-free, approaching that of the general population by 7 years after diagnosis. These results emphasize the importance of individualized, long-term follow-up to address both recurrence risk and survivorship needs.
Vertebral metastatic disease: A paradigm shift
Nguyen, Annee , Trivedi, Trupti, O’Callaghan, Ellen, Yoo, Seeley , Ahmed, Ramzy , Ramos, Rafael De La Garza, Charest-Morin, Raphaële , Sciubba, Daniel, Shin, John H, Laufer, I., Barzilai, Ori, Gokaslan, Z., Sahgal, Arjun, Weber, Michael, Sullivan, Patricia L. Zadnik, Dea, Nicolas, Mullikin, Trey C. , Goodwin, C Rory, Goodwin, C. Rory , Clarke, Michelle, Dea, Nicolas , Goodwin, C Rory , Trivedi, Trupti , O’Callaghan, Ellen , Zachem, Tanner J. , Ramos, Rafael De la Garza , Bilsky, Mark H. , Sciubba, Daniel M. , Clarke, Michelle J. , Tatsui, Claudio Esteves , Laufer, Ilya , Barzilai, Ori , Gokaslan, Ziya L., Sahgal, Arjun , Dea, Nicolas , Lazáry, Áron

Mayo Clinic

Neuro-Oncology Advances | March 20, 2026 | Volume: 8 | Issue: Supplement_3 | Pages: iii21-iii36

10.1093/noajnl/vdag011 | PMID 42221982 Get It

Abstract Vertebral metastatic disease results from many types of cancer and can have a devastating impact on patient mobility, psychological health, quality of life, and ultimately overall patient survival. However, the development of radiotherapy and surgical techniques has rapidly surged in conjunction with ongoing advances in basic science and translational studies. In this review, we discuss the paradigm shift in our understanding of the epidemiology and treatment algorithms for spinal oncology, ranging from preoperative optimization strategies, radiation and surgical techniques, the utilization of molecular markers and targeted therapeutics in medical oncology, and prognostication tools that underscore a new multidisciplinary approach to spinal oncology care.
Inside Front Cover: On the Discorhabdins Leading to the Aleutianamine Ring System: A One‐Step in Situ Transformation Characterized Through Computational and Experimental Studies and Its Implications on Biosynthesis, Synthesis, and Pharmacology (Angew. Chem
Potluri, Abhay , Bland, Alison M. , Flipse, Samuel M., Hanna, George S., Wagner, Ryan T. , Ho, Thai H., Hoff, Gerald R., Stone, R.N., Tius, Marcus A. , Tantillo, Dean J., Hamann, Mark T., Dickinson, Cody F. , Hanna, George S. , Robertson, Keith D. , Sprague, Daniel J. , Tantillo, Dean J , Hamann, Mark T

Mayo Clinic

Angewandte Chemie | March 19, 2026 | Volume: 138 | Issue: 17 | Pages: No page available

10.1002/ange.2026-m1603034200 Get It

Inside Front Cover: On the Discorhabdins Leading to the Aleutianamine Ring System: A One‐Step in Situ Transformation Characterized Through Computational and Experimental Studies and Its Implications on Biosynthesis, Synthesis, and Pharmacology (Angew. Chem
Potluri, Abhay , Bland, Alison M. , Flipse, Samuel M., Hanna, George S., Wagner, Ryan T. , Ho, Thai H., Hoff, Gerald R., Stone, R.N., Tius, Marcus A. , Tantillo, Dean J., Hamann, Mark T., Dickinson, Cody F. , Hanna, George S. , Robertson, Keith D. , Sprague, Daniel J. , Tantillo, Dean J , Hamann, Mark T

Mayo Clinic

Angewandte Chemie International Edition | March 19, 2026 | Volume: 65 | Issue: 17 | Pages: No page available

10.1002/anie.2026-m1603034200 Get It